Modulation of Therapeutic Response
Modulation of Therapeutic Response
批准号:
10262691
负责人:
James Mitchell
金额:
$138.88万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
AddressAttentionBlood VesselsBlood flowCDK4 geneClinicalClinical TrialsDrug CombinationsElectron Spin Resonance SpectroscopyGoalsHIF1A geneHeat-Shock Proteins 90HumanImageIn VitroIonizing radiationLactate DehydrogenaseMagnetic Resonance ImagingMalignant Epithelial CellMeasurementMetabolicMetabolismModificationMolecularMolecular TargetNormal tissue morphologyOxidative PhosphorylationOxygenPancreatic carcinomaPharmaceutical PreparationsPhysiologyProcessProductionPyruvateRadiationRadiation Dose UnitRadiation Induced DNA DamageRadiation OncologyRadiation ToleranceRadiation induced damageRadiation therapyRadiation-Protective AgentsRadiation-Sensitizing AgentsRadiosensitizationResearchResearch DesignStromal Cell-Derived Factor 1TherapeuticTissuesTranslatingTreatment EfficacyTumor TissueXenograft procedurecancer clinical trialcancer therapychemotherapyfractionated radiationimprovedin vivoinhibitor/antagonistinterestmetabolic imagingmolecular imagingmolecular markernon-invasive monitornovelpre-clinicalpre-clinical researchpreclinical studyradiation effectradiation responseradioresistantrepairedresponsetargeted agenttreatment responsetumortumor growthtumor metabolismtumor microenvironmentvasculogenesis
中文摘要
为了提高癌症的治疗水平,辐射损伤的修饰受到了极大的关注。各种化疗和/或分子靶向药物与辐射的相互作用正在研究中,以确定是否可以使肿瘤更敏感,或使正常组织对放射治疗更具抵抗力。中心目标是确定将导致净治疗收益的方法,从而改善癌症的放射治疗。该项目的目标之一是定义和更好地了解肿瘤生理学的这些方面,包括细胞和分子过程以及肿瘤微环境对治疗反应的影响。增强肿瘤对辐射的反应,而不增强给定治疗范围内的正常组织的能力是可取的。我们完成了一种新型HSP90抑制剂和一种CDK4/6抑制剂作为辐射增敏剂的初步临床前研究(体外和体内)。两种药物都观察到了显著的体外辐射剂量修正因子,异种移植研究表明,药物与分次辐射的结合导致了辐射敏感性的增强。此外,我们已经确定了有助于评估这两种药物治疗效果的分子生物标记物。这两种药物都有可能转化为人体临床试验。一项最初使用CDK4/6抑制剂(Abemaciclib)的新发现被证实与另一种完全不同的试剂HSP90抑制剂(AT13387)一起使用。当与放射联合使用时,两种药物都会抑制肿瘤血管生成,这是放射后的一个过程,使肿瘤重新获得血管供应,从而导致肿瘤再生。在过去的一年里,我们把重点放在了确定血管生成抑制的机制上,我们发现这两种药物都能抑制HIF-1α和SDF-1。我们目前正在进行研究,以确定这种抑制的机制。我们继续评估一些代谢抑制剂作为辐射调节剂的工作假设,即抑制新陈代谢(例如,减少ATP产生)将削弱辐射诱导的DNA损伤的修复。体外研究表明,一种新型乳酸脱氢酶抑制剂(LDHAi)可增强人胰腺癌细胞的放射敏感性。使用该制剂的初步异种移植研究表明,单用药物可显著延缓肿瘤生长,但不能增强放射反应。这一发现促使我们获得了一种氧化磷酸化抑制剂,其想法是将这两种药物(LDHAi和OxPhos抑制剂)与辐射结合使用,以确定对肿瘤反应的影响。我们已经证明,当LDHAi和OxPhos抑制剂结合起来时,与单独使用辐射相比,提供了更多的辐射增敏作用。我们还在使用13C-丙酮酸MRI对肿瘤代谢进行非侵入性监测,以评估肿瘤代谢的变化,以及针对肿瘤血流的MRI研究。这些临床前研究将为在肿瘤放射增敏的临床人体试验中考虑这些药物提供必要的信息。总体而言,我们已经确定了一些临床前方法来启动人类放射肿瘤学临床试验,以调节肿瘤的辐射效应。
英文摘要
In the interest of improving cancer treatment, considerable attention has been placed on the modification of radiation damage. The interaction of a variety of chemotherapy and/or molecularly targeted agents with radiation is under study to determine if tumors can be made more sensitive or normal tissues more resistant to radiation treatment. The central aim is to identify approaches that will result in a net therapeutic gain, thus improving cancer treatment with radiation. One goal of the project is to define and better understand those aspects of tumor physiology, including cellular and molecular processes and the influence of the tumor microenvironment on treatment response. The ability to enhance the response of the tumor to radiation, without enhancing normal tissue within a given treatment field is desirable. We finished initial pre-clinical studies of a novel HSP90 inhibitor and a CDK4/6 inhibitor as a radiation sensitizers (in vitro and in vivo). Significant in vitro radiation dose modification factors have been observed with both agents and xenograft studies indicate that the combination of the drug with fractionated radiation results in enhanced radiosensitivity. Further, we have identified molecular biomarkers that will be helpful in assessing treatment efficacy for both agents. Both agents have potential of being translated into human clinical trials. A new discovery, initially made using the CDK4/6 inhibitor (abemaciclib) was confirmed to be operational with a completely different agent, the HSP90 inhibitor (AT13387). When combined with radiation both agents inhibited tumor vasculogenesis, which is a process following radiation that resupplies the tumor with blood vessels resulting in tumor regrowth. We have placed a major emphasis this past year on defining the mechanism of vasculogenesis inhibition which we have found that both agents inhibit HIF-1alpha and SDF-1. We are currently conducting studies to determine the mechanism of this inhibition. We continue to evaluate a number of metabolic inhibitors as radiation modifiers under the working hypothesis that inhibition of metabolism (for example, decreased ATP production) will diminish the repair of radiation-induced DNA damage. In vitro studies have shown that a novel lactate dehydrogenase inhibitor (LDHAi) enhances the radiosensitivity of human pancreatic carcinoma cells. Preliminary xenograft studies with this agent have shown a significant tumor growth delay with drug alone, but no enhancement of the radiation response. This finding has prompted us to obtain an inhibitor of oxidative phosphorylation with the idea of using both agents (LDHAi and OxPhos inhibitior) combined with radiation to determine the impact on tumor response. We have shown that the combination of LDHAi and the OxPhos inhibitor when combined with radiation provides more radiosensitization than is observed for each agent alone with radiation. We are also conducting non-invasive monitoring of tumor metabolism using 13C-pyruvate MRI to assess changes in tumor metabolism as well as MRI studies that address tumor blood flow. These pre-clinical studies will provide the necessary information to consider these agents in a clinical human trial for tumor radiosensitization. Collectively, we have identified a number of pre-clinical approaches to initiate human radiation oncology clinical trials for modulation of radiation effects on tumors.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Nitroxides as Protectors Against Oxidative Stress
-
批准号:10487178
-
项目类别:
-
资助金额:$23.68万
-
财政年份:--
-
负责人:James Mitchell
-
依托单位:
Modulation of Therapeutic Response
-
批准号:8554011
-
项目类别:
-
资助金额:$66.27万
-
财政年份:--
-
负责人:James Mitchell
-
依托单位:
Modulation of Therapeutic Response
-
批准号:8350044
-
项目类别:
-
资助金额:$70.69万
-
财政年份:--
-
负责人:James Mitchell
-
依托单位:
Modulation of Therapeutic Response
-
批准号:9154244
-
项目类别:
-
资助金额:$67.78万
-
财政年份:--
-
负责人:James Mitchell
-
依托单位:
Protection against Radiation-Induced Carcinogenesis
-
批准号:10702438
-
项目类别:
-
资助金额:$114.64万
-
财政年份:--
-
负责人:James Mitchell
-
依托单位:
Protection against Radiation-Induced Carcinogenesis
-
批准号:8349242
-
项目类别:
-
资助金额:$32.13万
-
财政年份:--
-
负责人:James Mitchell
-
依托单位:
Redox Imaging using Nitroxides and MRI
-
批准号:8349161
-
项目类别:
-
资助金额:$55.7万
-
财政年份:--
-
负责人:James Mitchell
-
依托单位:
Nitroxides as Protectors Against Oxidative Stress
-
批准号:8938387
-
项目类别:
-
资助金额:$63.42万
-
财政年份:--
-
负责人:James Mitchell
-
依托单位:
Nitroxides as Protectors Against Oxidative Stress
-
批准号:10262693
-
项目类别:
-
资助金额:$27.78万
-
财政年份:--
-
负责人:James Mitchell
-
依托单位:
Modulation of Therapeutic Response
-
批准号:8158259
-
项目类别:
-
资助金额:$64.92万
-
财政年份:--
-
负责人:James Mitchell
-
依托单位:
Protection against Radiation-Induced Carcinogenesis
-
批准号:9153721
-
项目类别:
-
资助金额:$65.79万
-
财政年份:--
-
负责人:James Mitchell
-
依托单位:
Protection against Radiation-Induced Carcinogenesis
-
批准号:8937900
-
项目类别:
-
资助金额:$63.42万
-
财政年份:--
-
负责人:James Mitchell
-
依托单位:
Nitroxides as Protectors Against Oxidative Stress
-
批准号:10926566
-
项目类别:
-
资助金额:$58.43万
-
财政年份:--
-
负责人:James Mitchell
-
依托单位:
Modulation of Therapeutic Response
-
批准号:10487176
-
项目类别:
-
资助金额:$118.41万
-
财政年份:--
-
负责人:James Mitchell
-
依托单位:
Imaging Probe Development Center
-
批准号:8746870
-
项目类别:
-
资助金额:$370.3万
-
财政年份:--
-
负责人:James Mitchell
-
依托单位:
Redox Imaging using Nitroxides and MRI
-
批准号:8552827
-
项目类别:
-
资助金额:$30.12万
-
财政年份:--
-
负责人:James Mitchell
-
依托单位:
Redox Imaging using Nitroxides and MRI
-
批准号:7592935
-
项目类别:
-
资助金额:$31.76万
-
财政年份:--
-
负责人:James Mitchell
-
依托单位:
Modulation of Therapeutic Response
-
批准号:10702987
-
项目类别:
-
资助金额:$143.3万
-
财政年份:--
-
负责人:James Mitchell
-
依托单位:
Modulation of Therapeutic Response
-
批准号:10926564
-
项目类别:
-
资助金额:$175.3万
-
财政年份:--
-
负责人:James Mitchell
-
依托单位:
Nitroxides as Protectors Against Oxidative Stress
-
批准号:8763677
-
项目类别:
-
资助金额:$54.34万
-
财政年份:--
-
负责人:James Mitchell
-
依托单位:
国内基金
海外基金
多模态超声VisTran-Attention网络评估早期子宫颈癌保留生育功能手术可行性
-
批准号:--
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2022
-
负责人:郑巧
-
依托单位:
Ultrasomics-Attention孪生网络早期精准评估肝内胆管癌免疫治疗的研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:陈立达
-
依托单位:
多模态超声VisTran-Attention网络评估早期子宫颈癌保留生育功能手术可行性
-
批准号:82202156
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.0万元
-
批准年份:2022
-
负责人:郑巧
-
依托单位: